Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Alzheimer Disease | 151 | 2025 | 766 | 22.260 |
Why?
|
Antibodies, Monoclonal, Humanized | 21 | 2025 | 490 | 6.770 |
Why?
|
Indans | 29 | 2017 | 53 | 4.580 |
Why?
|
Cholinesterase Inhibitors | 29 | 2017 | 90 | 4.490 |
Why?
|
Piperidines | 29 | 2017 | 198 | 4.220 |
Why?
|
Cognition Disorders | 28 | 2016 | 555 | 4.220 |
Why?
|
Amyloid beta-Peptides | 21 | 2025 | 206 | 4.100 |
Why?
|
Neuropsychological Tests | 56 | 2021 | 924 | 3.340 |
Why?
|
Cognition | 30 | 2022 | 736 | 3.040 |
Why?
|
Activities of Daily Living | 24 | 2021 | 405 | 2.950 |
Why?
|
Nootropic Agents | 18 | 2017 | 25 | 2.690 |
Why?
|
Dementia | 27 | 2016 | 448 | 2.410 |
Why?
|
Aged, 80 and over | 78 | 2025 | 6372 | 2.240 |
Why?
|
Aged | 134 | 2025 | 19098 | 2.140 |
Why?
|
Clinical Trials as Topic | 24 | 2024 | 1088 | 2.130 |
Why?
|
Cognitive Dysfunction | 7 | 2023 | 225 | 2.090 |
Why?
|
Double-Blind Method | 33 | 2025 | 1590 | 1.930 |
Why?
|
Memantine | 9 | 2012 | 17 | 1.830 |
Why?
|
Psychiatric Status Rating Scales | 25 | 2016 | 797 | 1.700 |
Why?
|
Disease Progression | 31 | 2024 | 2025 | 1.690 |
Why?
|
Drug Approval | 2 | 2023 | 40 | 1.540 |
Why?
|
Mental Status and Dementia Tests | 6 | 2023 | 17 | 1.330 |
Why?
|
Excitatory Amino Acid Antagonists | 6 | 2016 | 96 | 1.320 |
Why?
|
Brain | 18 | 2025 | 2964 | 1.310 |
Why?
|
Severity of Illness Index | 30 | 2021 | 2839 | 1.260 |
Why?
|
Humans | 188 | 2025 | 123223 | 1.230 |
Why?
|
Male | 121 | 2025 | 60117 | 1.210 |
Why?
|
Middle Aged | 84 | 2025 | 26016 | 1.180 |
Why?
|
Psychometrics | 14 | 2021 | 657 | 1.160 |
Why?
|
Female | 123 | 2025 | 65549 | 1.130 |
Why?
|
Plaque, Amyloid | 4 | 2022 | 63 | 1.080 |
Why?
|
Feasibility Studies | 2 | 2024 | 753 | 1.020 |
Why?
|
Amnesia | 4 | 2011 | 20 | 1.010 |
Why?
|
Patient Care | 2 | 2021 | 100 | 0.990 |
Why?
|
Apolipoproteins E | 9 | 2014 | 190 | 0.960 |
Why?
|
United States Food and Drug Administration | 4 | 2023 | 148 | 0.920 |
Why?
|
Amyloid Precursor Protein Secretases | 2 | 2013 | 62 | 0.860 |
Why?
|
Azepines | 2 | 2013 | 61 | 0.850 |
Why?
|
Treatment Outcome | 35 | 2024 | 12141 | 0.850 |
Why?
|
Alanine | 2 | 2013 | 181 | 0.840 |
Why?
|
Amyloidosis | 1 | 2022 | 65 | 0.780 |
Why?
|
Mental Status Schedule | 14 | 2016 | 44 | 0.730 |
Why?
|
Antiparkinson Agents | 4 | 2024 | 65 | 0.720 |
Why?
|
Positron-Emission Tomography | 8 | 2024 | 288 | 0.680 |
Why?
|
Research | 2 | 2021 | 263 | 0.670 |
Why?
|
Medical Futility | 1 | 2020 | 36 | 0.670 |
Why?
|
Pseudobulbar Palsy | 2 | 2016 | 4 | 0.650 |
Why?
|
Quinidine | 2 | 2016 | 9 | 0.650 |
Why?
|
Dextromethorphan | 2 | 2016 | 11 | 0.650 |
Why?
|
Geriatric Assessment | 9 | 2012 | 169 | 0.630 |
Why?
|
Longitudinal Studies | 9 | 2017 | 1309 | 0.620 |
Why?
|
Biomarkers | 22 | 2022 | 2946 | 0.600 |
Why?
|
Indoles | 2 | 2009 | 180 | 0.590 |
Why?
|
Parkinson Disease | 4 | 2024 | 671 | 0.560 |
Why?
|
Magnetic Resonance Imaging | 10 | 2025 | 3546 | 0.540 |
Why?
|
Drug Discovery | 3 | 2017 | 170 | 0.540 |
Why?
|
Mental Recall | 2 | 2015 | 142 | 0.540 |
Why?
|
Markov Chains | 1 | 2016 | 83 | 0.500 |
Why?
|
Models, Statistical | 4 | 2018 | 475 | 0.480 |
Why?
|
tau Proteins | 8 | 2022 | 189 | 0.470 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2013 | 1068 | 0.470 |
Why?
|
Oligonucleotides | 2 | 2024 | 88 | 0.440 |
Why?
|
Intelligence Tests | 4 | 2012 | 57 | 0.420 |
Why?
|
Vitamin E | 6 | 2010 | 64 | 0.420 |
Why?
|
Attention | 6 | 2012 | 197 | 0.420 |
Why?
|
Language | 9 | 2016 | 202 | 0.420 |
Why?
|
Huntington Disease | 2 | 2024 | 141 | 0.410 |
Why?
|
Drug Therapy, Combination | 4 | 2012 | 1151 | 0.410 |
Why?
|
Regression Analysis | 4 | 2013 | 771 | 0.400 |
Why?
|
Functional Laterality | 6 | 1999 | 181 | 0.400 |
Why?
|
International Cooperation | 7 | 2022 | 160 | 0.400 |
Why?
|
Early Diagnosis | 5 | 2018 | 178 | 0.380 |
Why?
|
Interview, Psychological | 1 | 2012 | 97 | 0.380 |
Why?
|
Reproducibility of Results | 13 | 2021 | 2830 | 0.360 |
Why?
|
Patient Dropouts | 2 | 2016 | 52 | 0.360 |
Why?
|
Advisory Committees | 6 | 2024 | 148 | 0.350 |
Why?
|
Caregivers | 8 | 2024 | 572 | 0.340 |
Why?
|
Health Policy | 2 | 2009 | 213 | 0.340 |
Why?
|
Apolipoprotein E4 | 8 | 2016 | 43 | 0.340 |
Why?
|
Attitude to Health | 2 | 2009 | 259 | 0.340 |
Why?
|
Multicenter Studies as Topic | 4 | 2016 | 263 | 0.330 |
Why?
|
Memory | 8 | 2012 | 361 | 0.320 |
Why?
|
Patient Compliance | 2 | 2009 | 467 | 0.310 |
Why?
|
Basal Ganglia Diseases | 4 | 2000 | 27 | 0.310 |
Why?
|
United States | 16 | 2023 | 10637 | 0.310 |
Why?
|
Evidence-Based Medicine | 1 | 2012 | 622 | 0.310 |
Why?
|
Adult | 20 | 2024 | 29072 | 0.310 |
Why?
|
Trust | 1 | 2009 | 75 | 0.300 |
Why?
|
Patient Selection | 3 | 2013 | 685 | 0.300 |
Why?
|
Algorithms | 7 | 2016 | 1593 | 0.300 |
Why?
|
Research Design | 4 | 2021 | 685 | 0.300 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2018 | 68 | 0.290 |
Why?
|
Insulin | 1 | 2013 | 1200 | 0.290 |
Why?
|
Polymorphism, Genetic | 1 | 2011 | 809 | 0.290 |
Why?
|
Amyloidogenic Proteins | 3 | 2022 | 6 | 0.290 |
Why?
|
Academic Medical Centers | 1 | 2009 | 299 | 0.280 |
Why?
|
Depression | 4 | 2012 | 1217 | 0.280 |
Why?
|
Drug Industry | 4 | 2017 | 46 | 0.260 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 2 | 1997 | 105 | 0.260 |
Why?
|
Informed Consent | 1 | 2009 | 341 | 0.260 |
Why?
|
Asymptomatic Diseases | 2 | 2022 | 78 | 0.250 |
Why?
|
Dementia, Vascular | 3 | 2015 | 16 | 0.250 |
Why?
|
Supranuclear Palsy, Progressive | 2 | 2016 | 29 | 0.250 |
Why?
|
alpha-Synuclein | 2 | 2024 | 114 | 0.240 |
Why?
|
Treatment Failure | 4 | 2014 | 338 | 0.240 |
Why?
|
Primary Health Care | 1 | 2011 | 753 | 0.230 |
Why?
|
Cohort Studies | 14 | 2022 | 4710 | 0.230 |
Why?
|
Models, Psychological | 2 | 2010 | 136 | 0.230 |
Why?
|
Phenylcarbamates | 2 | 2006 | 15 | 0.230 |
Why?
|
Psychotic Disorders | 2 | 1995 | 140 | 0.230 |
Why?
|
Observer Variation | 5 | 2011 | 296 | 0.220 |
Why?
|
Injections, Subcutaneous | 1 | 2024 | 126 | 0.220 |
Why?
|
Likelihood Functions | 3 | 2012 | 112 | 0.220 |
Why?
|
Nerve Degeneration | 2 | 1996 | 126 | 0.220 |
Why?
|
Aphasia | 2 | 1993 | 14 | 0.210 |
Why?
|
Medical History Taking | 1 | 2003 | 106 | 0.210 |
Why?
|
Biomedical Research | 1 | 2009 | 518 | 0.210 |
Why?
|
China | 3 | 2021 | 240 | 0.210 |
Why?
|
Age of Onset | 6 | 2014 | 581 | 0.210 |
Why?
|
Geriatrics | 1 | 2003 | 72 | 0.210 |
Why?
|
Cerebrovascular Circulation | 2 | 1997 | 434 | 0.210 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2021 | 1682 | 0.210 |
Why?
|
Prospective Studies | 8 | 2021 | 6040 | 0.210 |
Why?
|
Antibodies, Monoclonal | 3 | 2023 | 1009 | 0.210 |
Why?
|
Alleles | 2 | 2005 | 1603 | 0.200 |
Why?
|
Practice Patterns, Physicians' | 1 | 2008 | 713 | 0.200 |
Why?
|
Case-Control Studies | 10 | 2019 | 3249 | 0.200 |
Why?
|
Computer Communication Networks | 1 | 2022 | 15 | 0.200 |
Why?
|
Education | 4 | 2009 | 105 | 0.200 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2017 | 530 | 0.200 |
Why?
|
Data Interpretation, Statistical | 2 | 2016 | 229 | 0.190 |
Why?
|
Time Factors | 7 | 2017 | 6221 | 0.190 |
Why?
|
Tacrine | 1 | 2001 | 2 | 0.190 |
Why?
|
Visual Perception | 2 | 2004 | 125 | 0.190 |
Why?
|
Proportional Hazards Models | 5 | 2016 | 1306 | 0.190 |
Why?
|
Lipids | 3 | 2019 | 515 | 0.190 |
Why?
|
Risk Factors | 10 | 2020 | 10015 | 0.190 |
Why?
|
Factor Analysis, Statistical | 3 | 2012 | 226 | 0.190 |
Why?
|
Self-Assessment | 3 | 2006 | 66 | 0.180 |
Why?
|
Genetic Predisposition to Disease | 6 | 2019 | 3084 | 0.180 |
Why?
|
Diarrhea | 2 | 2015 | 316 | 0.180 |
Why?
|
Psychomotor Performance | 3 | 2012 | 188 | 0.180 |
Why?
|
Genotype | 7 | 2017 | 2542 | 0.180 |
Why?
|
Sensitivity and Specificity | 7 | 2011 | 2026 | 0.180 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2018 | 71 | 0.170 |
Why?
|
Cross-Sectional Studies | 5 | 2015 | 3378 | 0.170 |
Why?
|
Prevalence | 5 | 2016 | 2406 | 0.170 |
Why?
|
Motor Activity | 3 | 2004 | 522 | 0.170 |
Why?
|
Analysis of Variance | 3 | 2011 | 1008 | 0.170 |
Why?
|
Extremities | 1 | 2000 | 82 | 0.160 |
Why?
|
Social Behavior | 3 | 2012 | 207 | 0.160 |
Why?
|
Awareness | 4 | 2005 | 81 | 0.160 |
Why?
|
DNA Copy Number Variations | 3 | 2014 | 941 | 0.160 |
Why?
|
Microglia | 2 | 2017 | 96 | 0.160 |
Why?
|
Heptanoic Acids | 2 | 2010 | 77 | 0.160 |
Why?
|
Diagnosis, Differential | 5 | 2011 | 1877 | 0.150 |
Why?
|
Thiadiazines | 1 | 2018 | 1 | 0.150 |
Why?
|
Cyclic S-Oxides | 1 | 2018 | 2 | 0.150 |
Why?
|
Drug Combinations | 2 | 2016 | 270 | 0.150 |
Why?
|
Mental Processes | 3 | 2009 | 41 | 0.150 |
Why?
|
Immunity | 1 | 2019 | 181 | 0.150 |
Why?
|
Aggression | 2 | 2010 | 226 | 0.150 |
Why?
|
Phospholipase C gamma | 1 | 2017 | 17 | 0.140 |
Why?
|
Pyrroles | 2 | 2010 | 177 | 0.140 |
Why?
|
Verbal Behavior | 1 | 1997 | 52 | 0.140 |
Why?
|
Elder Abuse | 2 | 2008 | 24 | 0.140 |
Why?
|
Predictive Value of Tests | 6 | 2017 | 2112 | 0.140 |
Why?
|
Genetic Loci | 1 | 2019 | 333 | 0.140 |
Why?
|
Lewy Body Disease | 2 | 2015 | 18 | 0.140 |
Why?
|
Blood Pressure | 1 | 2003 | 1325 | 0.140 |
Why?
|
Pyrrolidinones | 1 | 2017 | 17 | 0.140 |
Why?
|
Movement Disorders | 1 | 2000 | 221 | 0.140 |
Why?
|
Cerebral Cortex | 2 | 2000 | 448 | 0.140 |
Why?
|
Receptors, Immunologic | 1 | 2017 | 110 | 0.140 |
Why?
|
Statistics as Topic | 2 | 2016 | 250 | 0.140 |
Why?
|
Acetamides | 1 | 2017 | 49 | 0.130 |
Why?
|
Data Accuracy | 1 | 2016 | 25 | 0.130 |
Why?
|
Self Concept | 3 | 2005 | 157 | 0.130 |
Why?
|
Health Services Accessibility | 1 | 2021 | 594 | 0.130 |
Why?
|
Frontotemporal Dementia | 1 | 2015 | 40 | 0.120 |
Why?
|
Nervous System | 1 | 1996 | 128 | 0.120 |
Why?
|
Antipsychotic Agents | 2 | 2017 | 375 | 0.120 |
Why?
|
Membrane Glycoproteins | 1 | 2017 | 413 | 0.120 |
Why?
|
Headache | 1 | 2015 | 108 | 0.120 |
Why?
|
Judgment | 2 | 2012 | 34 | 0.120 |
Why?
|
Patient Outcome Assessment | 1 | 2015 | 94 | 0.120 |
Why?
|
Immunity, Innate | 1 | 2017 | 372 | 0.120 |
Why?
|
Follow-Up Studies | 5 | 2017 | 5049 | 0.110 |
Why?
|
Intention to Treat Analysis | 1 | 2014 | 56 | 0.110 |
Why?
|
Korea | 2 | 2011 | 35 | 0.110 |
Why?
|
Gene Dosage | 2 | 2013 | 441 | 0.110 |
Why?
|
Oligopeptides | 1 | 2014 | 118 | 0.110 |
Why?
|
alpha7 Nicotinic Acetylcholine Receptor | 1 | 2014 | 57 | 0.110 |
Why?
|
Interpersonal Relations | 1 | 2015 | 225 | 0.110 |
Why?
|
Spasm | 2 | 2009 | 48 | 0.110 |
Why?
|
Placebos | 3 | 2021 | 238 | 0.110 |
Why?
|
Endpoint Determination | 2 | 2013 | 53 | 0.110 |
Why?
|
Receptors, Complement 3b | 1 | 2013 | 8 | 0.110 |
Why?
|
Apathy | 1 | 2012 | 9 | 0.110 |
Why?
|
Mental Health | 1 | 1996 | 346 | 0.100 |
Why?
|
Neuropsychology | 1 | 2013 | 23 | 0.100 |
Why?
|
Dopamine Agents | 1 | 2012 | 28 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2017 | 2586 | 0.100 |
Why?
|
Brain Damage, Chronic | 1 | 1992 | 30 | 0.100 |
Why?
|
Aging | 4 | 2011 | 1173 | 0.100 |
Why?
|
Dominance, Cerebral | 1 | 1992 | 54 | 0.100 |
Why?
|
Cerebral Infarction | 1 | 1992 | 46 | 0.100 |
Why?
|
Fetal Hypoxia | 1 | 2012 | 13 | 0.100 |
Why?
|
Antioxidants | 3 | 2009 | 338 | 0.100 |
Why?
|
Binomial Distribution | 1 | 2012 | 3 | 0.100 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2012 | 110 | 0.100 |
Why?
|
Genome-Wide Association Study | 3 | 2019 | 1642 | 0.100 |
Why?
|
Biostatistics | 1 | 2012 | 10 | 0.100 |
Why?
|
Hobbies | 1 | 2012 | 4 | 0.100 |
Why?
|
Databases, Bibliographic | 1 | 2012 | 20 | 0.100 |
Why?
|
Cardiovascular Diseases | 1 | 2004 | 1863 | 0.100 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 2012 | 62 | 0.100 |
Why?
|
Neurologic Examination | 1 | 1992 | 195 | 0.100 |
Why?
|
Executive Function | 1 | 2012 | 106 | 0.100 |
Why?
|
Memory Disorders | 2 | 2012 | 235 | 0.100 |
Why?
|
Linear Models | 4 | 2013 | 669 | 0.100 |
Why?
|
Diagnostic Imaging | 3 | 2012 | 271 | 0.100 |
Why?
|
Orientation | 1 | 2012 | 50 | 0.100 |
Why?
|
Hand | 1 | 1992 | 102 | 0.100 |
Why?
|
Movement | 2 | 2008 | 167 | 0.100 |
Why?
|
Problem Solving | 1 | 2012 | 64 | 0.100 |
Why?
|
Serum | 1 | 2011 | 46 | 0.100 |
Why?
|
Disabled Persons | 1 | 2013 | 99 | 0.100 |
Why?
|
Social Adjustment | 1 | 2012 | 85 | 0.100 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 2012 | 121 | 0.100 |
Why?
|
Bias | 1 | 2012 | 125 | 0.090 |
Why?
|
Urinary Tract Infections | 1 | 2015 | 293 | 0.090 |
Why?
|
Meta-Analysis as Topic | 1 | 2012 | 153 | 0.090 |
Why?
|
Plasma | 1 | 2011 | 96 | 0.090 |
Why?
|
Lithium Chloride | 1 | 2011 | 8 | 0.090 |
Why?
|
Sphingomyelins | 1 | 2011 | 16 | 0.090 |
Why?
|
Diabetes Mellitus | 2 | 2013 | 849 | 0.090 |
Why?
|
Palate, Soft | 1 | 1990 | 16 | 0.090 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2011 | 29 | 0.090 |
Why?
|
Voice Disorders | 1 | 1990 | 18 | 0.090 |
Why?
|
Bayes Theorem | 1 | 2012 | 278 | 0.090 |
Why?
|
Intelligence | 2 | 2013 | 98 | 0.090 |
Why?
|
Myoclonus | 1 | 1990 | 32 | 0.090 |
Why?
|
Texas | 5 | 2011 | 3560 | 0.090 |
Why?
|
Publishing | 1 | 2011 | 108 | 0.090 |
Why?
|
Retrospective Studies | 4 | 2023 | 16033 | 0.090 |
Why?
|
Sex Factors | 2 | 2004 | 1260 | 0.090 |
Why?
|
Blood Proteins | 1 | 2010 | 116 | 0.090 |
Why?
|
Quality of Health Care | 2 | 2006 | 391 | 0.080 |
Why?
|
Tumor Suppressor Proteins | 1 | 2013 | 467 | 0.080 |
Why?
|
Congresses as Topic | 1 | 2011 | 170 | 0.080 |
Why?
|
Hippocampus | 3 | 2017 | 820 | 0.080 |
Why?
|
Psychomotor Agitation | 1 | 2010 | 56 | 0.080 |
Why?
|
Histamine Antagonists | 1 | 2009 | 17 | 0.080 |
Why?
|
Weight Loss | 1 | 2013 | 478 | 0.080 |
Why?
|
Nausea | 1 | 2009 | 97 | 0.080 |
Why?
|
Government Agencies | 1 | 2009 | 11 | 0.080 |
Why?
|
Cross-Cultural Comparison | 3 | 1998 | 60 | 0.080 |
Why?
|
Health Services Administration | 1 | 2009 | 11 | 0.080 |
Why?
|
Drug and Narcotic Control | 1 | 2009 | 18 | 0.080 |
Why?
|
Survival | 2 | 2006 | 19 | 0.080 |
Why?
|
National Health Programs | 1 | 2009 | 19 | 0.080 |
Why?
|
Computer Simulation | 1 | 2012 | 635 | 0.080 |
Why?
|
Public Policy | 1 | 2009 | 51 | 0.080 |
Why?
|
Russia | 1 | 2008 | 39 | 0.080 |
Why?
|
Professional-Patient Relations | 1 | 2009 | 85 | 0.080 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2009 | 94 | 0.080 |
Why?
|
Europe | 2 | 2010 | 374 | 0.070 |
Why?
|
Databases, Factual | 3 | 2011 | 1168 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1292 | 0.070 |
Why?
|
Educational Status | 2 | 2011 | 270 | 0.070 |
Why?
|
Motor Skills | 1 | 2008 | 85 | 0.070 |
Why?
|
Reaction Time | 2 | 2005 | 172 | 0.070 |
Why?
|
Galantamine | 2 | 2006 | 10 | 0.070 |
Why?
|
Cost of Illness | 2 | 2010 | 242 | 0.070 |
Why?
|
Rivastigmine | 2 | 2006 | 17 | 0.070 |
Why?
|
Primary Prevention | 2 | 2006 | 164 | 0.070 |
Why?
|
Proxy | 1 | 2006 | 15 | 0.070 |
Why?
|
Technetium Tc 99m Exametazime | 2 | 1997 | 8 | 0.070 |
Why?
|
Organotechnetium Compounds | 2 | 1997 | 12 | 0.070 |
Why?
|
Speech | 2 | 2000 | 57 | 0.070 |
Why?
|
Nuclear Proteins | 1 | 2013 | 1265 | 0.070 |
Why?
|
Pilot Projects | 2 | 2008 | 1388 | 0.070 |
Why?
|
Skin Neoplasms | 1 | 2013 | 796 | 0.070 |
Why?
|
Oximes | 2 | 1997 | 48 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2007 | 586 | 0.070 |
Why?
|
Central Nervous System Agents | 1 | 2006 | 15 | 0.060 |
Why?
|
Mass Screening | 1 | 2011 | 788 | 0.060 |
Why?
|
Delusions | 2 | 1995 | 17 | 0.060 |
Why?
|
Mental Competency | 1 | 2006 | 51 | 0.060 |
Why?
|
Managed Care Programs | 1 | 2006 | 61 | 0.060 |
Why?
|
ROC Curve | 3 | 2017 | 557 | 0.060 |
Why?
|
Hallucinations | 2 | 1995 | 26 | 0.060 |
Why?
|
Anticholesteremic Agents | 1 | 2008 | 230 | 0.060 |
Why?
|
Genetic Variation | 1 | 2012 | 1480 | 0.060 |
Why?
|
Self Disclosure | 1 | 2005 | 24 | 0.060 |
Why?
|
Monoamine Oxidase Inhibitors | 1 | 2024 | 12 | 0.060 |
Why?
|
Recovery of Function | 1 | 2007 | 437 | 0.060 |
Why?
|
Interviews as Topic | 2 | 2003 | 368 | 0.060 |
Why?
|
Neuroprotective Agents | 1 | 2006 | 150 | 0.060 |
Why?
|
Area Under Curve | 3 | 2011 | 313 | 0.060 |
Why?
|
Incidence | 5 | 2010 | 3048 | 0.060 |
Why?
|
Levodopa | 1 | 2024 | 90 | 0.060 |
Why?
|
Monoamine Oxidase | 1 | 2024 | 11 | 0.060 |
Why?
|
Ambulatory Care Facilities | 1 | 2006 | 229 | 0.060 |
Why?
|
Self Care | 1 | 2006 | 212 | 0.060 |
Why?
|
Administration, Intravenous | 1 | 2024 | 143 | 0.060 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2019 | 151 | 0.060 |
Why?
|
Consensus | 2 | 2022 | 612 | 0.060 |
Why?
|
Anthropometry | 1 | 2004 | 197 | 0.060 |
Why?
|
Disease Models, Animal | 2 | 2012 | 4273 | 0.060 |
Why?
|
Gene Expression Profiling | 3 | 2017 | 1682 | 0.060 |
Why?
|
Linguistics | 2 | 1993 | 18 | 0.050 |
Why?
|
Memory, Short-Term | 1 | 2004 | 140 | 0.050 |
Why?
|
N-Methylaspartate | 1 | 2003 | 29 | 0.050 |
Why?
|
Reference Values | 1 | 2004 | 697 | 0.050 |
Why?
|
Neuroimaging | 2 | 2018 | 332 | 0.050 |
Why?
|
Sampling Studies | 1 | 2003 | 74 | 0.050 |
Why?
|
Comorbidity | 3 | 2002 | 1496 | 0.050 |
Why?
|
Patients | 1 | 2024 | 121 | 0.050 |
Why?
|
Behavioral Symptoms | 1 | 2003 | 25 | 0.050 |
Why?
|
Carbamates | 1 | 2003 | 57 | 0.050 |
Why?
|
History, 19th Century | 2 | 1993 | 117 | 0.050 |
Why?
|
Tremor | 1 | 2024 | 129 | 0.050 |
Why?
|
Drug Administration Schedule | 3 | 2016 | 730 | 0.050 |
Why?
|
Task Performance and Analysis | 1 | 2003 | 95 | 0.050 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 1 | 2022 | 34 | 0.050 |
Why?
|
Amyloid | 1 | 2022 | 65 | 0.050 |
Why?
|
Electrocardiography | 1 | 2008 | 958 | 0.050 |
Why?
|
Videotape Recording | 1 | 2002 | 57 | 0.050 |
Why?
|
Alcohol Drinking | 1 | 2004 | 337 | 0.050 |
Why?
|
Surveys and Questionnaires | 5 | 2017 | 3670 | 0.050 |
Why?
|
Smoking | 2 | 2004 | 1031 | 0.050 |
Why?
|
Observational Studies as Topic | 1 | 2022 | 84 | 0.050 |
Why?
|
Brain Edema | 2 | 2013 | 69 | 0.050 |
Why?
|
History, 20th Century | 2 | 1993 | 383 | 0.050 |
Why?
|
Prosopagnosia | 1 | 2001 | 1 | 0.050 |
Why?
|
Adaptive Clinical Trials as Topic | 1 | 2021 | 7 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2004 | 866 | 0.050 |
Why?
|
Learning | 1 | 2004 | 362 | 0.050 |
Why?
|
Metabolic Syndrome | 1 | 2004 | 330 | 0.050 |
Why?
|
Practice Guidelines as Topic | 5 | 1998 | 1262 | 0.040 |
Why?
|
Quality of Life | 2 | 2001 | 1929 | 0.040 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2000 | 16 | 0.040 |
Why?
|
Brain Mapping | 2 | 2012 | 399 | 0.040 |
Why?
|
Atrophy | 2 | 2013 | 226 | 0.040 |
Why?
|
Estrogen Replacement Therapy | 1 | 2000 | 44 | 0.040 |
Why?
|
Prognosis | 2 | 2016 | 4514 | 0.040 |
Why?
|
Neurofilament Proteins | 1 | 2019 | 28 | 0.040 |
Why?
|
Drug Tolerance | 1 | 1999 | 40 | 0.040 |
Why?
|
Hypertension | 2 | 2004 | 1287 | 0.040 |
Why?
|
Age Factors | 1 | 2004 | 2802 | 0.040 |
Why?
|
Drug Design | 2 | 2009 | 146 | 0.040 |
Why?
|
Haplotypes | 1 | 2019 | 519 | 0.040 |
Why?
|
European Union | 1 | 2017 | 17 | 0.040 |
Why?
|
Protein Interaction Maps | 1 | 2017 | 76 | 0.030 |
Why?
|
Neurodegenerative Diseases | 1 | 2000 | 253 | 0.030 |
Why?
|
Synaptic Transmission | 1 | 1999 | 348 | 0.030 |
Why?
|
Depressive Disorder, Major | 1 | 2002 | 398 | 0.030 |
Why?
|
Linkage Disequilibrium | 1 | 2017 | 310 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2017 | 657 | 0.030 |
Why?
|
Dysarthria | 1 | 1996 | 21 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2019 | 351 | 0.030 |
Why?
|
Temporal Lobe | 1 | 1997 | 116 | 0.030 |
Why?
|
Spain | 1 | 2016 | 53 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2012 | 2390 | 0.030 |
Why?
|
Perfusion | 1 | 1997 | 197 | 0.030 |
Why?
|
Gene Frequency | 1 | 2017 | 713 | 0.030 |
Why?
|
Parietal Lobe | 1 | 1995 | 42 | 0.030 |
Why?
|
Frontal Lobe | 1 | 1995 | 111 | 0.030 |
Why?
|
Survival Analysis | 2 | 2009 | 1472 | 0.030 |
Why?
|
Odds Ratio | 1 | 2017 | 1243 | 0.030 |
Why?
|
Datasets as Topic | 1 | 2014 | 85 | 0.030 |
Why?
|
Genetic Heterogeneity | 1 | 2014 | 123 | 0.030 |
Why?
|
Speech-Language Pathology | 1 | 1993 | 13 | 0.030 |
Why?
|
Language Disorders | 1 | 1993 | 24 | 0.030 |
Why?
|
Stroke | 2 | 2016 | 958 | 0.030 |
Why?
|
Thailand | 1 | 2013 | 34 | 0.030 |
Why?
|
History, 18th Century | 1 | 1993 | 69 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 1997 | 1414 | 0.030 |
Why?
|
Brain Chemistry | 1 | 2013 | 122 | 0.030 |
Why?
|
Brain Diseases | 1 | 1996 | 296 | 0.030 |
Why?
|
Speech Disorders | 1 | 1993 | 42 | 0.030 |
Why?
|
PAX6 Transcription Factor | 1 | 2012 | 37 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 2017 | 2696 | 0.030 |
Why?
|
Paired Box Transcription Factors | 1 | 2012 | 75 | 0.030 |
Why?
|
Registries | 3 | 2009 | 1394 | 0.030 |
Why?
|
Genetic Testing | 1 | 2019 | 997 | 0.030 |
Why?
|
Exome | 1 | 2017 | 1041 | 0.030 |
Why?
|
Ambulatory Care | 1 | 1995 | 377 | 0.030 |
Why?
|
Family | 1 | 1995 | 578 | 0.020 |
Why?
|
Corpus Callosum | 1 | 1992 | 98 | 0.020 |
Why?
|
Self Report | 1 | 2015 | 510 | 0.020 |
Why?
|
Aphasia, Broca | 1 | 1991 | 1 | 0.020 |
Why?
|
Qualitative Research | 1 | 2015 | 520 | 0.020 |
Why?
|
Emotions | 2 | 2005 | 359 | 0.020 |
Why?
|
Gene-Environment Interaction | 1 | 2012 | 120 | 0.020 |
Why?
|
Cerebrospinal Fluid | 1 | 2011 | 93 | 0.020 |
Why?
|
Authorship | 1 | 2011 | 29 | 0.020 |
Why?
|
Cytoskeletal Proteins | 1 | 2013 | 268 | 0.020 |
Why?
|
Decision Making | 1 | 1996 | 653 | 0.020 |
Why?
|
Eye Proteins | 1 | 2012 | 217 | 0.020 |
Why?
|
Brain Injuries, Traumatic | 1 | 2016 | 370 | 0.020 |
Why?
|
Receptors, Odorant | 1 | 2011 | 36 | 0.020 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2011 | 64 | 0.020 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2011 | 100 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2013 | 269 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2014 | 1012 | 0.020 |
Why?
|
Visual Cortex | 1 | 2012 | 109 | 0.020 |
Why?
|
Triglycerides | 1 | 2013 | 562 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2014 | 761 | 0.020 |
Why?
|
Community Mental Health Services | 1 | 2010 | 38 | 0.020 |
Why?
|
Cholinergic Antagonists | 1 | 2010 | 51 | 0.020 |
Why?
|
Astrocytes | 1 | 2012 | 251 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2012 | 543 | 0.020 |
Why?
|
Family Relations | 1 | 2010 | 69 | 0.020 |
Why?
|
Gene Deletion | 1 | 2013 | 793 | 0.020 |
Why?
|
Social Environment | 1 | 2010 | 120 | 0.020 |
Why?
|
Anti-Anxiety Agents | 1 | 2010 | 72 | 0.020 |
Why?
|
Federal Government | 1 | 2009 | 15 | 0.020 |
Why?
|
Comparative Genomic Hybridization | 1 | 2011 | 574 | 0.020 |
Why?
|
Nursing Homes | 1 | 2010 | 95 | 0.020 |
Why?
|
Organ Size | 1 | 2010 | 412 | 0.020 |
Why?
|
Saccharomyces cerevisiae | 1 | 2012 | 422 | 0.020 |
Why?
|
Models, Genetic | 1 | 2012 | 766 | 0.020 |
Why?
|
Synapses | 1 | 2012 | 448 | 0.020 |
Why?
|
Reference Standards | 2 | 2002 | 240 | 0.020 |
Why?
|
Phosphorylation | 1 | 2012 | 1608 | 0.020 |
Why?
|
Down-Regulation | 1 | 2011 | 697 | 0.020 |
Why?
|
Academies and Institutes | 1 | 2009 | 84 | 0.020 |
Why?
|
Handwriting | 1 | 2008 | 8 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2011 | 1081 | 0.020 |
Why?
|
Mental Disorders | 2 | 2013 | 821 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2009 | 134 | 0.020 |
Why?
|
Models, Biological | 1 | 1993 | 1441 | 0.020 |
Why?
|
Hospitals, Veterans | 1 | 2010 | 354 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2012 | 810 | 0.020 |
Why?
|
Heterozygote | 1 | 2009 | 672 | 0.020 |
Why?
|
Computational Biology | 1 | 2011 | 798 | 0.020 |
Why?
|
Pain | 1 | 2010 | 470 | 0.020 |
Why?
|
Depressive Disorder | 1 | 2010 | 449 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2010 | 557 | 0.020 |
Why?
|
Hygiene | 1 | 2006 | 25 | 0.020 |
Why?
|
Logistic Models | 1 | 2010 | 1793 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 2011 | 1114 | 0.020 |
Why?
|
Demography | 1 | 2005 | 239 | 0.010 |
Why?
|
Mice | 2 | 2012 | 17503 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2005 | 235 | 0.010 |
Why?
|
Disability Evaluation | 1 | 2005 | 190 | 0.010 |
Why?
|
Genomics | 1 | 2012 | 1477 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2006 | 501 | 0.010 |
Why?
|
Phenotype | 1 | 2013 | 4228 | 0.010 |
Why?
|
Behavior | 1 | 2003 | 75 | 0.010 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 714 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2006 | 451 | 0.010 |
Why?
|
Medicare | 1 | 2006 | 424 | 0.010 |
Why?
|
Hypercholesterolemia | 1 | 2003 | 226 | 0.010 |
Why?
|
Survival Rate | 1 | 2005 | 1996 | 0.010 |
Why?
|
Risk Assessment | 1 | 2009 | 3316 | 0.010 |
Why?
|
Animals | 2 | 2012 | 33759 | 0.010 |
Why?
|
Neurology | 1 | 2002 | 108 | 0.010 |
Why?
|
Pregnancy | 1 | 2012 | 7161 | 0.010 |
Why?
|
Population Surveillance | 1 | 2002 | 386 | 0.010 |
Why?
|
Heart Diseases | 1 | 2003 | 482 | 0.010 |
Why?
|
Hysterectomy | 1 | 2000 | 185 | 0.010 |
Why?
|
Local Government | 1 | 1997 | 3 | 0.010 |
Why?
|
Retirement | 1 | 1997 | 18 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 1997 | 111 | 0.010 |
Why?
|
Adolescent | 1 | 2012 | 19110 | 0.010 |
Why?
|
Wechsler Scales | 1 | 1992 | 21 | 0.010 |
Why?
|
Writing | 1 | 1992 | 59 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 1991 | 2058 | 0.000 |
Why?
|